BIO panel with Roche’s James Sabry, Spark’s Federico Mingozzi and Adaptive’s Harlan Robins imagines a world where cell and gene therapies are preferred over small molecules and antibodies.

Private Company Edition: In addition to Erasca’s big series B round, Mabwell reportedly brought in $278m. Also, Kurma, Venrock and Section bring the number of new VC funds in April to eight, raising $5.89bn, and former AveXis execs launched the new gene therapy venture Taysha.

Hospira has been frustrated again in long-running litigation concerning its Retacrit biosimilar to Amgen’s Epogen, in a case closely watched by the biopharma industry as it addressed what constitutes a safe harbor for a biosimilar applicant.

Celltrion and Pfizer are now two for two in their legal battles with Janssen over US patents shielding the originator's Remicade (infliximab), with a US Court of Appeals once again siding with the biosimilars developers.